BioHeart is a biotechnology corporation that develops devices designed to aid in the diagnosis, monitoring, and treatment of cardiovascular diseases. The company aims to improve heart disease sufferers’ quality of life, while attempting to reduce the normally exorbitant costs associated with cardiologic treatments.
In a press statement issued on Thursday, the company announced that it had received a United States Patent and Trademark Office Notice of Allowance for nine new patent claims, which pertain to using electrical signals to stimulate heart cell regeneration. BioHeart’s new technologies are a significant step forward in the field of cardiovascular treatment in that they utilize fundamental electro-chemical genetic instructions to “teach” undifferentiated stem cells to grow into heart muscle. This process will aid heart failure victims in regrowing damaged heart tissue, and could potentially save lives.
“The best way to predict the future is to create it,” said BioHeart’s director of surgical and clinical research, Juan Chachques, “This invention could be regarded in the future as one of the most important developments ever in the fight to reduce the death rate from heart failure.”
BioHeart currently holds the rights to thirty-six related U.S. patents, and has submitted claims for over four hundred.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment